β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1

Journal of Cellular Physiology

Volumn 228, Issue 7, 2013, Pages 1601-1609

  Goel, Hira Lal ^a   Sayeed, Aejaz ^b,c   Breen, Michael ^a   Zarif, Matthew J ^a   Garlick, David S ^a   Leav, Irwin ^a   Davis, Roger J ^a   Fitzgerald, Thomas J ^a   Morrione, Andrea ^c   Hsieh, Chung Cheng ^a   Liu, Qin ^b,d   Dicker, Adam P ^c   Altieri, Dario C ^b,d   Languino, Lucia R ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Prostate Cancer Discovery and Development Program   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INDUCED RESISTANCE; IONIZING RADIATION; LASER CAPTURE MICRODISSECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION;

ANIMALS; ANTIGENS, CD29; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 8; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 84875532867     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24323     Document Type: Article

References (53)

1. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK, Languino LR. 2007. The integrin-growth factor receptor duet. J Cell Physiol 213: 649-653.
2. Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM. 2007. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67: 1155-1162.
3. Baserga R, Peruzzi F, Reiss K. 2003. The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877.
4. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. 2007. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 5: 61-71.
5. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, Hsieh CL. 2005. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12: 634-643.
6. 1 integrin function in vivo: Adhesion, migration and more. Cancer Metastasis Rev 24: 403-411.
7. Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. 1997. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 90: 315-323.
8. Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z, Foster B. 2011. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs 29: 674-679.
9. Das M, Garlick DS, Greiner DL, Davis RJ. 2011. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25: 634-645.
10. Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ. 1997. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277: 693-696.
11. 1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest 122: 1529-1540.
12. 1 integrin gene expression in mice. Genes Dev 9: 1896-1908.
13. Fitzgerald TJ, Wang T, Goel HL, Huang J, Stein G, Lian J, Davis RJ, Doxsey S, Balaji KC, Aronowitz J, Languino LR. 2008. Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev Anticancer Ther 8: 967-974.
14. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. 2003. Fibronectin protects prostate cancer cells from tumor necrosis factor α-induced apoptosis via the AKT/Survivin pathway. J Biol Chem 278: 50402-50411.
15. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. 2012. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy. Clin Cancer Res 18: 1015-1027.
16. 1 integrins. J Cell Biol 166: 407-418.
17. 1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 65: 6692-6700.
18. 1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. Cancer Res 69: 5374-5382.
19. 1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. J Cell Physiol 224: 210-217.
20. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. 1995. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443.
21. Hubner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ. 2012. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci USA 109: 12046-12051.
22. Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110: 673-687.
23. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873.
24. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW. 2001. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 61: 2833-2837.
25. Kirsch DG, Haigis K, Santiago P, Tukeshia S, Korsmeyer S, Jacks T. 2005. Using mouse genetics to dissect the cellular target of radiation in the GI syndrome. Int J Radiat Oncol Biol Phys 63: S469.
26. 1-integrin function. EMBO J 26: 2832-2842.
27. Lawton CA, DeSilvio M, Roach M III, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR, Jr. 2007. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69: 646-655.
28. Levresse V, Butterfield L, Zentrich E, Heasley LE. 2000. Akt negatively regulates the cJun N-terminal kinase pathway in PC12 cells. J Neurosci Res 62: 799-808.
29. Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. 2005. RACK1 mediates activation of JNK by protein kinase C. Mol Cell 19: 309-320.
30. 1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model. Sci Rep 2: 526.
31. 1 and fibronectin. Cancer Res 70: 5238-5248.
32. 1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66: 1526-1535.
33. 1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 68: 4398-4405.
34. 1 integrin in skin: Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J Cell Biol 150: 1149-1160.
35. 1 integrin: A phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 14: 7924-7929.
36. 1A integrins. J Cell Physiol 227: 751-758.
37. 1A with protein kinase B/Akt, p130Cas and paxillin contribute to regulation of radiation survival. Radiother Oncol 76: 129-134.
38. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C. 1999. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668.
39. 1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106: 10290-10295.
40. Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. 2013. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer 119: 681-690.
41. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E. 2009. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
42. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. 2010. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035.
43. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM. 2008. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68: 3495-3504.
44. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS, Jr., Davis RJ. 2004. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 18: 2905-2915.
45. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569.
46. Wang T, Languino LR, Lian J, Stein G, Blute M, Fitzgerald TJ. 2012. Molecular targets for radiation oncology in prostate cancer. Front Oncol 1: 1-11.
47. Weston CR, Davis RJ. 2007. The JNK signal transduction pathway. Curr Opin Cell Biol 19: 142-149.
48. 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159-170.
49. Whitmarsh AJ, Davis RJ. 2007. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 26: 3172-3184.
50. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P. 2001. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69.
51. 1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67: 659-664.
52. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisca I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG. 2012. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 118: 4053-4062.
53. Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE. 2007. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest 117: 2962-2973.